HC Wainwright Reaffirms Buy Rating for BioNTech (NASDAQ:BNTX)

HC Wainwright restated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note published on Wednesday morning, Benzinga reports. They currently have a $113.00 target price on the stock.

Other equities analysts have also recently issued reports about the stock. BMO Capital Markets lowered their price target on shares of BioNTech from $123.00 to $122.00 and set an outperform rating on the stock in a report on Tuesday, May 7th. Canaccord Genuity Group reaffirmed a buy rating and issued a $171.00 price objective on shares of BioNTech in a research note on Thursday, March 21st. JPMorgan Chase & Co. reduced their price objective on shares of BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a research note on Friday, March 22nd. The Goldman Sachs Group reduced their price objective on shares of BioNTech from $113.00 to $100.00 and set a neutral rating for the company in a research note on Wednesday, February 28th. Finally, Evercore ISI started coverage on shares of BioNTech in a research report on Tuesday, May 14th. They set an inline rating and a $100.00 target price for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, BioNTech has an average rating of Hold and an average target price of $111.70.

BioNTech Trading Down 0.0 %

NASDAQ BNTX opened at $80.36 on Wednesday. BioNTech has a twelve month low of $80.02 and a twelve month high of $125.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The stock has a market cap of $19.10 billion, a price-to-earnings ratio of 160.72 and a beta of 0.27. The firm’s 50 day moving average price is $92.22 and its two-hundred day moving average price is $94.70.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.60). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $203.69 million for the quarter, compared to analysts’ expectations of $589.96 million. Equities analysts anticipate that BioNTech will post -2 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BNTX. GAMMA Investing LLC raised its position in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after buying an additional 150 shares during the last quarter. CWM LLC increased its stake in BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after acquiring an additional 217 shares during the period. Frazier Financial Advisors LLC bought a new stake in BioNTech in the fourth quarter valued at about $30,000. Covestor Ltd bought a new stake in BioNTech in the third quarter valued at about $32,000. Finally, First Horizon Advisors Inc. bought a new stake in BioNTech in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.